Giulia D'ARcangelo

Giulia D'ARcangelo

Auto-generated profile, based on publicly available information

Giulia D'ARcangelo

Pediatric Gastroenterology and Liver Unit, Department of Maternal Infantile and Urological Sciences, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy; Gastroenterology, Hepatology and Cystic Fibrosis Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico di Milano, Milan, Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2013 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
MAMarina Aloi
Marina Aloi
GDGiulia D'ARcangelo
Giulia D'ARcangelo
FPFabrizio Pofi
Fabrizio Pofi
FVFrancesca Vassallo
Francesca Vassallo
VRValentina Rizzo
Valentina Rizzo
SCSalvatore Cucchiara
Salvatore Cucchiara
Clinical variables and disease course of pediatric ulcerative colitis (UC) have been poorly reported. The aim of this study was to retrospectively describe the phenotype and disease course of pediatric onset UC diagnosed at a tertiary referral Center for Pediatric Gastroenterology. 110 patients with a diagnosis of UC were identified at our Department database. Records were reviewed for disease location and behavior at the diagnosis, family history for inflammatory bowel disease, pattern changes at the follow-up, need of surgery and cumulative risk for colectomy. Thirty-five % of patients had an early-onset disease (0-7 years). At the diagnosis, 29% had proctitis, 22% left-sided colitis, 15% extensive colitis and 34% pancolitis. Fifteen % presented with a rectal sparing, while a patchy colonic inflammation was reported in 18%. Rectal sparing was significantly related to the younger age (p: <0.05). Disease extension at the follow up was reported in 29% of pts. No clinical variables at the diagnosis were related to the subsequent extension of the disease. The cumulative rates of colectomy were 9% at 2 year and 14% at 5 years. An extensive disease as well as acute severe colitis and corticosteroid therapy at the diagnosis were significantly associated with an increased risk of colectomy. Pediatric UC is extensive and severe at the diagnosis, with an overall high rate of disease extension at the follow-up. Endoscopic atypical features are common in young children. The colectomy rate is related to the location and severity of the disease at the diagnosis.

1 July 2015 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
MAMarina Aloi
Marina Aloi
LTLuciana Tromba
Luciana Tromba
VRValentina Rizzo
Valentina Rizzo
GDGiulia D'ARcangelo
Giulia D'ARcangelo
ADAnna Dilillo
Anna Dilillo
FVFranca Viola
Franca Viola

1 June 2018 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Closed access
MAMarina Aloi
Marina Aloi
MBMatteo Bramuzzo
Matteo Bramuzzo
SASerena Arrigo
Serena Arrigo
CRClaudio Romano
Claudio Romano
GDGiulia D'ARcangelo
Giulia D'ARcangelo
SGSIGENP IBD Working Group
SIGENP IBD Working Group

1 June 2019 in Journal of Pediatric Gastroenterology and Nutrition
Verified
Journal Article
Open access
GDGiulia D'ARcangelo
Giulia D'ARcangelo
SOSalvatore Oliva
Salvatore Oliva
ADAnna Dilillo
Anna Dilillo
FVFranca Viola
Franca Viola
FCFortunata Civitelli
Fortunata Civitelli
MAMarina Aloi
Marina Aloi
Objectives: We aimed to identify early noninvasive predictors of clinical and endoscopic remission in children with Crohn disease (CD) under infliximab (IFX).Methods: Prospective observational study conducted in children with moderate‐to‐severe CD starting IFX. All patients underwent weighted pediatric CD activity index (wPCDAI) assessment, C‐reactive protein and fecal calprotectin (FC) at week 0, 14, and 48. Endoscopy was performed at 0 and 48 weeks. The primary outcome was to determine the ability of 14‐week wPCDAI, C‐reactive protein, and FC to predict 1‐year steroid‐free clinical remission and mucosal healing. As a secondary outcome we evaluated their concordance with Simple Endoscopic Score for CD (SES‐CD) at week 48.Results: Forty‐one children were enrolled. At 1 year, 21 (51%) and 16 (39%) were in clinical and endoscopic remission. Only combined postinduction FC and wPCDAI were able to predict 1‐year clinical and endoscopic remission (hazard ratio 4.81 [95% confidence interval 1.76–20.45], P = 0.05 and hazard ratio 5.51 [95% confidence interval 1.83–26.9], P = 0.03). One‐year SES‐CD moderately correlated with FC (r = 0.52; P = 0.001). The FC cut‐off value for mucosal healing was 120.5 μg/g (area under the curve 0.863, 83% sensitivity, 75.5% specificity; P = 0.005). The concordance between wPCDAI and SES‐CD was excellent and good for severe disease and remission (k 0.87 and 0.76).Conclusions: Post induction FC combined with wPCDAI can predict 1‐year clinical and endoscopic response to IFX in pediatric CD. FC shows a moderate correlation with SES‐CD, whereas wPCDAI has a good concordance with endoscopic remission or severe disease, but not with mild and moderate disease.

3 May 2020 in Expert Review of Gastroenterology & Hepatology
Verified
Journal Article
Closed access
SCSalvatore Cucchiara
Salvatore Cucchiara
GDGiulia D’aRcangelo
Giulia D’aRcangelo
SISara Isoldi
Sara Isoldi
MAMarina Aloi
Marina Aloi
LSLaura Stronati
Laura Stronati
Introduction. Traditional management of patients with Crohn’s disease includes symptoms and quality of life improvement. With the advent of biological agents, mucosal healing has become an achievable goal, documented through endoscopy. However, due to the transmural nature of inflammation, the prevention of bowel damage should be included in the aims of a targeted therapeutic strategy. Areas Covered. Updated literature has been searched in PubMed from 2008 to 2020. This review focuses on the state of the art in the innovative therapeutic goals in Crohn’s disease, also considering still controversial aspects and future research topics in the management of Crohn’s disease. Expert Opinion. Although a widely agreed view supports the notion that mucosal healing and bowel damage control may promote beneficial outcomes (i.e. reduction in hospitalization and surgical rates, avoidance of steroids), long term robust data are still missing. On the other hand, the development of -omics techniques have expanded our knowledge of the pathogenetic mechanism underlying inflammatory bowel disease and opened up new horizons in precision or personalized medicine.

1 July 2016 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
MAMarina Aloi
Marina Aloi
GDGiulia Dʼarcangelo
Giulia Dʼarcangelo
MBMatteo Bramuzzo
Matteo Bramuzzo
MGMarco Gasparetto
Marco Gasparetto
MMMassimo Martinelli
Massimo Martinelli
SMStefano Martelossi
Stefano Martelossi
We aimed at describing the efficacy of azathioprine (AZA) in pediatric ulcerative colitis, comparing the outcomes of early (0-6 months) versus late (6-24 months) initiation of therapy. Children with ulcerative colitis treated with AZA within 24 months of diagnosis were included. Corticosteroid (CS)-free remission and mucosal healing (MH), assessed by endoscopy or fecal calprotectin, at 12 months were the primary outcomes. Patients were also compared for CS-free remission and MH, need for treatment escalation or surgery, number of hospitalizations, and adverse events during a 24-month follow-up. A total of 121 children entered the study (median age 10.5 ± 4.0 years, 59% girls). Seventy-six (63%) started AZA between 0 and 6 months (early group) and 45 (37%) started between 6 and 24 months (late group). Seventy-five percent and 53% of patients in the early and late group, respectively, received CS at the diagnosis (P = 0.01). CS-free remission at 1 year was achieved by 30 (50%) of the early and 23 (57%) of the late patients (P = 0.54). MH occurred in 37 (37%) patients at 1 year, with no difference between the 2 groups (33% early, 42% late; P = 0.56). No difference was found for the other outcomes. Introduction of AZA within 6 months of diagnosis seems not more effective than later treatment to achieve CS-free remission in pediatric ulcerative colitis. MH does not depend on the timing of AZA initiation; however, because of the incomplete comparability of the 2 groups at the diagnosis and the use of fecal calprotectin as a surrogate marker of MH, our results should be further confirmed by prospective studies.